Institution Directory

Clinical trials at Stanford Medicine

Sites in Stanford & Palo Alto, CA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 2:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1366

Shown on this page

Current sort

Live official records

Conditions: Healthy Adult Participants
Interventions: Microbiome bank; Other
Lead sponsor: Sean Spencer; Other
Eligibility: 18 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Lymphoid Leukemia
Interventions: Questionnaire for patients receiving therapy; Other
Lead sponsor: Stanford University; Other
Eligibility: Up to 26 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2038
U.S. locations: 22
States / cities: Tucson, Arizona • Duarte, California • Palo Alto, California + 19 more

Conditions: Cesarean Delivery, General Anesthesia
Interventions: Not listed
Lead sponsor: Yale University; Other
Eligibility: 15 Years to 55 Years · Female only
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 34
States / cities: Little Rock, Arkansas • San Francisco, California • Stanford, California + 29 more

Conditions: Preclinical Alzheimer's Disease, Early Preclinical Alzheimer's Disease
Interventions: Lecanemab, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 55 Years to 80 Years
Enrollment: 1,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2031
U.S. locations: 72
States / cities: Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 61 more

Conditions: Solid Tumor
Interventions: Farletuzumab ecteribulin, Prednisone, Prednisolone, Dexamethasone, Lenvatinib; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 24
States / cities: Tucson, Arizona • Little Rock, Arkansas • Palo Alto, California + 19 more

Conditions: Lymphoma, Mantle Cell Lymphoma
Interventions: rituximab, Bendamustine, bortezomib, lenalidomide; Biological · Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years
Enrollment: 373 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2031
U.S. locations: 416
States / cities: Anchorage, Alaska • Antioch, California • Fremont, California + 283 more

Conditions: Lymphoblastic Leukemia
Interventions: Dexamethasone, Mitoxantrone, PEG asparaginase, Bortezomib, Vorinostat, Mercaptopurine, Methotrexate, Blinatumomab, Ziftomenib; Drug
Lead sponsor: Tanja Andrea Gruber; Other
Eligibility: Up to 1 Year
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2033
U.S. locations: 17
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 14 more

Conditions: Breast Neoplasms
Interventions: endocrine therapy alone without radiotherapy; Other
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 50 Years to 69 Years · Female only
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 13
States / cities: Stanford, California • New Haven, Connecticut • Maywood, Illinois + 10 more

Conditions: Chronic Pain, Chronic Pain Syndrome, Chronic Pancreatitis, Hyperalgesia, Opioid Use Disorder, Opioid-Related Disorders, Opioid Dependence, Chronic Abdominal Pain, ERCP, Pancreatic Surgery
Interventions: Lacosamide; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 5
States / cities: Stanford, California • Indianapolis, Indiana • Rochester, Minnesota + 2 more

Conditions: Breast Cancer
Interventions: questionaire, blood or saliva sample; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 54 Years · Female only
Enrollment: 1,699 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2027
U.S. locations: 4
States / cities: Stanford, California • Iowa City, Iowa • New York, New York + 1 more

Conditions: Medulloblastoma, Glioblastoma Multiforme, Anaplastic Astrocytoma, High-grade Astrocytoma NOS, Anaplastic Oligodendroglioma, Anaplastic Ependymoma, Ependymoma, Diffuse Intrinsic Pontine Glioma
Interventions: SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years, SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥1 and <10 years, SurVaxM for patients with non-relapsed DIPG post radiation-therapy ages ≥1 and ≤21 years; Biological
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 21 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 13
States / cities: Los Angeles, California • Palo Alto, California • Aurora, Colorado + 10 more

Conditions: Anarthria, Dysarthria, Tetraplegia, Spinal Cord Injuries, Amyotrophic Lateral Sclerosis, Brain Stem Infarctions, Locked in Syndrome, Muscular Dystrophies
Interventions: BrainGate Neural Interface System; Device
Lead sponsor: Leigh R. Hochberg, MD, PhD.; Other
Eligibility: 18 Years to 80 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Stanford, California • Boston, Massachusetts

About this Stanford Medicine institution page

What this page lists: ClinicalTrials.gov records that list Stanford Medicine in Stanford & Palo Alto, CA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Stanford Medicine

Filter and sort this campus

Live official records

Stanford University Microbiome Bank

Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy

The Society for Obstetric Anesthesia and Perinatology Research Network General Anesthesia Registry

AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma

TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

The IDEA Study (Individualized Decisions for Endocrine Therapy Alone)

STTEPP: Safety, Tolerability and Dose Limiting Toxicity of Lacosamide in Patients With Painful Chronic Pancreatitis

Study of Radiation Exposure and Bilateral Breast Cancer

A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma

Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia

About this Stanford Medicine institution page